Visfatin in juvenile obesity - the effect of obesity intervention and sex

European Journal of Clinical Investigation

Volumn 41, Issue 12, 2011, Pages 1284-1291

  Krzystek Korpacka, Malgorzata ^a   Patryn, Eliza ^a,b   Bednarz Misa, Iwona ^a   Hotowy, Katarzyna ^a   Noczynska, Anna ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adipocytokine; Insulin resistance; Metabolic syndrome; Obesity; Visfatin; Weight loss

Indexed keywords

INSULIN; INTERLEUKIN 6; LEPTIN; METFORMIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL;

ADOLESCENT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SEX DIFFERENCE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADIPOKINES; ADOLESCENT; AGE FACTORS; BODY MASS INDEX; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOKINES; FEMALE; HUMANS; INSULIN RESISTANCE; LEPTIN; MALE; METABOLIC SYNDROME X; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; SEX FACTORS; STATISTICS AS TOPIC; WEIGHT LOSS;

EID: 81255214946     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02538.x     Document Type: Article

References (42)

1. Moschen AR, Geiger S, Gerner R, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat Res 2010;690:95-101.
2. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30.
3. Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006;49:744-7.
4. Chang YC, Chang TJ, Lee WJ, Chuang LM. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Metabolism 2010;59:93-9.
5. Laudes M, Oberhauser F, Schulte DM, Freude S, Bilkovski R, Mauer J et al. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res 2010;42:268-73.
6. Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007;92:4783-91.
7. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Silva C, Rotellar F et al. Association of increased Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutr Metab Cardiovasc Dis 2011;21:245-53.
8. de Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O, Romero E. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients. Nutrition 2008;24:517-21.
9. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006;91:1578-81.
10. García-Fuentes E, García-Almeida JM, García-Arnés J, García-Serrano S, Rivas-Marín J, Gallego-Perales JL et al. Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity (Silver Spring) 2007;15:2391-5.
11. Dedoussis GV, Kapiri A, Samara A, Dimitriadis D, Lambert D, Pfister M et al. Visfatin: the link between inflammation and childhood obesity. Diabetes Care 2009;32:e71.
12. Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, Kawada Y et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 2008;16:384-8.
13. Krzystek-Korpacka M, Patryn E, Boehm D, Berdowska I, Zielinski B, Noczynska A. Advanced oxidation protein products (AOPPs) in juvenile overweight and obesity prior to and following weight reduction. Clin Biochem 2008;41:943-9.
14. Krzystek-Korpacka M, Patryn E, Kustrzeba-Wojcicka I, Chrzanowska J, Gamian A, Noczynska A. Gender-specific association of serum uric acid with metabolic syndrome and its components in juvenile obesity. Clin Chem Lab Med 2011;49:129-36.
15. Krzystek-Korpacka M, Patryn E, Kustrzeba-Wojcicka I, Chrzanowska J, Gamian A, Noczynska A. The effect of a one-year weight reduction program on serum uric acid in overweight/obese children and adolescents. Clin Chem Lab Med 2011;49:915-21.
16. Palczewska I, Niedzwiecka Z. Wskazniki rozwoju somatycznego dzieci i mlodziezy warszawskiej. (Indices of somatic development of children and adolescents in Warsaw). Med Wieku Rozw 2002;2(Suppl I): 52.
17. Atabek ME, Pirgon O. Assessment of insulin sensitivity from measurements in fasting state and during an oral glucose tolerance test in obese children. J Pediatr Endocrinol Metab 2007;20:187-95.
18. Matsuda M, De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-70.
19. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555-76.
20. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003;157:821-7.
21. American Heart Association Nutrition Committee; Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006;114:82-96.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
23. Rice-Evans CA, Diplock AT, Symons MCR. Techniques in Free Radical Research. Amsterdam: Elsevier Science Publishers BV; 1991.
24. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
25. Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O et al. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 2006;43:548-9.
26. Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 2008;79:412-8.
27. Dedoussis GV, Kapiri A, Samara A, Dimitriadis D, Lambert D, Pfister M et al. Expression of inflammatory molecules and associations with BMI in children. Eur J Clin Invest 2010;40:388-92.
28. Kolsgaard ML, Wangensteen T, Brunborg C, Joner G, Holven KB, Halvorsen B et al. Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome. Scand J Clin Lab Invest 2009;69:858-64.
29. Davutoglu M, Ozkaya M, Guler E, Garipardic M, Gursoy H, Karabiber H et al. Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices. Swiss Med Wkly 2009;139:22-7.
30. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 2007;92:666-72.
31. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006;91:3165-70.
32. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54:2911-6.
33. Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med 2005;11:344-7.
34. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005;185:R1-8.
35. Geer EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gend Med 2009;6:60-75.
36. Ibáñez L, Sebastiani G, Lopez-Bermejo A, Díaz M, Gómez-Roig MD, de Zegher F. Gender specificity of body adiposity and circulating adiponectin, visfatin, insulin, and insulin growth factor-I at term birth: relation to prenatal growth. J Clin Endocrinol Metab 2008;93:2774-8.
37. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008;34:2-11.
38. Yeckel CW, Weiss R, Dziura J, Taksali SE, Dufour S, Burgert TS et al. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 2004;89:1096-101.
39. Stofkova A. Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul 2010;44:25-36.
40. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm 2010;2010:535918.
41. Bo S, Ciccone G, Baldi I, Gambino R, Mandrile C, Durazzo M et al. Plasma visfatin concentrations after a lifestyle intervention were directly associated with inflammatory markers. Nutr Metab Cardiovasc Dis 2009;19:423-30.
42. Erdem G, Dogru T, Tasci I, Bozoglu E, Muhsiroglu O, Tapan S et al. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. Diabetes Res Clin Pract 2008;82:214-8.